Recently, CellCarta, a globally leading CRO laboratory in the biopharmaceutical industry, announced the establishment of the Global Digital Pathology and Artificial Intelligence Alliance.Dipath has become one of the first seven partners in the alliance, joining CellCarta’s digital pathology and AI collaborative ecosystem built for biopharmaceutical companies, to advance the application of pathology AI in biomarker research, new drug development, and companion diagnostics (CDx）Applications in Development.

The alliance’s initial cohort brings together seven innovative enterprises in digital pathology, artificial intelligence, and precision diagnostics, including Dipath. CellCarta positions it as a curated selection,AI-Agnostic (Technology-Neutral)collaborative ecosystem, leveraging its global laboratory network and clinical R&D capabilities, for biopharmaceutical companiesThe industry provides support ranging from technical assessment and validation to research applications. The alliance covers oncology, autoimmune diseases, Alzheimer's disease, and other indications, aiming toEmpower sponsors to advance biomarker discovery, patient stratification, clinical trial execution, and companion diagnostic planning, translating cutting-edge AI R&D concepts into empirical data applicable for clinical trials.For Dipath, joining the alliance is just the starting point,More importantly, the collaboration between the two parties has progressed from the alliance level to the implementation of specific companion diagnostic projects.

Dipath has long been dedicated to the “AI + pathology” sector, with core competencies spanning AI-based image analysis, whole-slide scanning, and digital pathology workflows. Oriented toward new drug development and companion diagnostics, it canProvides IHC quantification, pathological morphology quantification, and custom algorithm development to deliver pathology data capabilities for biomarker research and clinical trials.。

On the official CellCarta alliance page, Dipath is introduced as “an AI digital pathology company from China.”, featuring AI image analysis and whole-slide scanningDescribe the capabilities of the workflow platform, which can serve pathology research and biomarker development.”

After joining the alliance, both parties willIntegrate Dipath’s pathological AI capabilities with CellCarta’s global laboratory network and clinical R&D service system to further advance the application of AI in biomarker development and companion diagnostic research.

Becoming one of the founding members of CellCarta’s Global Digital Pathology and Artificial Intelligence Alliance, and advancing the implementation of specific CDx projects, marks a significant milestone in Dipath’s internationalization strategy. This achievement signifies an expansion beyond the overseas deployment of digital pathology products for hospitals, extending further into the global pharmaceutical industry’s value chain encompassing new drug development, clinical research, and companion diagnostics.

About CellCarta

As a globally leading CRO laboratory serving the biopharmaceutical industry, CellCarta holds CAP and CLIA accreditations for specific testing methods and facilities in Canada, the United States, Belgium, Australia, and China, providing diverse biomarker testing services and customized solutions to renowned pharmaceutical companies worldwide. By integrating analytical platforms including immunology, histopathology, proteomics, and genomics, complemented by sample management and logistics services, CellCarta supports the full lifecycle of drug development from research through late-stage clinical trials. Please visit cellcarta.com and connect with CellCarta on LinkedIn and X.

About Dipath

Dipath, founded in 2017, has dedicated two decades to the field of AI-powered digital pathology. Guided by its mission to “illuminate pathology with intelligence and make precision medicine accessible,” Dipath has emerged as a leading benchmark enterprise in China’s digital-intelligent pathology and AI diagnostics sector. The company has received over 200 honors, including recognition as a National High-Tech Enterprise, a Zhejiang Province “Specialized, Refined, Distinctive, and Innovative” SME, a Hangzhou “Quasi-Unicorn,” and a Zhejiang Province “Emerging Tech Dragon.” Since being classified as an enterprise above designated size in 2023, Dipath has maintained an annual revenue growth rate exceeding 70%, demonstrating robust momentum.

On January 6, 2026, Professor Yang Lin, founder of the company and head of the Artificial Intelligence and Biomedical Imaging Laboratory at Westlake University, donated equity to Westlake University on behalf of the enterprise. This move aims to deepen industry-academia-research-medical collaboration and foster high-quality development in the fields of medical-engineering interdisciplinary innovation and digital-intelligent pathology.

Core Advantages

    Top-tier R&D Strength

The R&D team has been deeply engaged in the field of pathology AI for over 20 years, with R&D centers established in Hangzhou, Shaanxi, and Guangdong. The company hosts a High-Tech Enterprise R&D Center and a Postdoctoral Workstation, with R&D personnel accounting for 60% of its workforce. It has led more than 40 national-level scientific research fund projects, published over 500 high-impact SCI papers, and accumulated more than 10,000 total citations.

    Full-Stack Independent Innovation

Leveraging a deep integration model of industry, academia, research, and medicine centered around Westlake University, the company has built a full-chain innovation system spanning from basic scientific research to clinical translation. Driven by its independently developed, end-to-end large AI models, it has constructed comprehensive pathological AI applications covering cellular, tissue, and molecular pathology scenarios. The company holds over 220 intellectual property rights, including more than 80 invention patents, and has obtained 25 Class II medical device registration certificates. It was selected as a winning entity in the AI medical device innovation challenge launched by the Ministry of Industry and Information Technology and the National Medical Products Administration, tackling key technological bottlenecks in the industry.

    Full-Scenario Product Matrix

Centered on the DeepPathAI Shendi Mofang foundational large model, we have developed product lines including ZhiJie, intelligent pathology, AI for cervical cytology, and large-model-powered scanners. By integrating cloud-based services such as intelligent remote consultation, pathology information management and quality control systems, intelligent standardized training systems, and digital pathology cloud storage, we provide a comprehensive solution for building fully digital and intelligent pathology departments covering all disease types and entire workflows.

     Large-Scale Clinical Implementation

Serving over 1,500 medical institutions, research organizations, and pharmaceutical companies globally; collaborating with domestic Grade-A tertiary hospitals to establish nearly 100 fully digital and intelligent pathology departments, jointly launching multiple specialty-specific large pathology models, and comprehensively enhancing the integrated capabilities in pathological diagnosis, education, and research. Conducted over 20,000 ZhiJie live-streaming teaching sessions, more than 30,000 real-time microscopic consultations and remote会诊, extending remote coverage to over a thousand hospitals nationwide, with support provided to 1,000 grassroots healthcare institutions.